An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations. Almost all patients who initially respond to an epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Shinichi, Kuno, Yasumasa, Hayai, Shunsaku, Teramachi, Ryo, Yamashita, Ryo, Saito, Yusuke, Higuchi, Kosuke, Nara, Yoshiharu, Ikeda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412784/
https://www.ncbi.nlm.nih.gov/pubmed/32762742
http://dx.doi.org/10.1186/s13256-020-02447-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412784/
https://www.ncbi.nlm.nih.gov/pubmed/32762742
http://dx.doi.org/10.1186/s13256-020-02447-0

Ejemplares similares